Navigation Links
versus in Medical Technology
... significantly greater A1C reduction, weight loss versus weight gain and fewer episodes of hypoglycemia." ... was 4 percent with exenatide once weekly versus 19 percent with Lantus for patients on metformin ... and 20 percent with exenatide once weekly versus 44 percent with Lantus for patients on metformin ...
... also significantly reduced SLE disease activity versus placebo based on a number of other measures, ... primary efficacy endpoint of superiority versus placebo at Week 52. A clinically and ... in both belimumab treatment groups, versus placebo, had their average prednisone dose ...
... with methotrexate plus placebo (0.29, 0.34 versus 1.1, respectively; p<0.001). In addition, ... plus placebo-treated patients (81%, 85% versus 67%, p less than or equal to 0.0001), as measured ... a post-hoc analysis of the AMBITION ( A ctemra versus M ethotrexate double- B lind I ...
... to placebo (5 percent for tadalafil 40 mg, versus 16 percent with placebo)(4,5). Additionally, the ... mg were headache (42 percent for tadalafil 40 mg, versus 15 percent with placebo), myalgia (14 percent for tadalafil 40 mg, versus 4 percent with placebo) and flushing (13 percent ...
... at 6, 12, 18 and 24 months for lorcaserin versus placebo were 2.1% vs. 1.9% (p=0.88), 2.7% vs. ... evaluated 10 mg of lorcaserin dosed twice daily versus placebo over a two-year treatment period in obese ... 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese ...
... five years) previously demonstrated by Avandia versus metformin and sulfonylurea in the ADOPT study. ... randomized to Avandia (61 events or 2.7 percent versus 29 events or 1.3 percent) (hazard ratio=2.10, 95 ... deaths from any cause (136 events or 6.1 percent versus 157 events or 7 percent for control) (hazard ...
... a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy ... using the Barnes Akathisia Scale) for lurasidone versus placebo. Lurasidone was well-tolerated ...
... combination of vandetanib 100mg with docetaxel versus docetaxel alone. The study enrolled 1391 patients ... study evaluating vandetanib 100mg plus pemetrexed versus pemetrexed alone. The study enrolled 534 patients ... study evaluating the efficacy of vandetanib 300mg versus erlotinib 150mg. The study enrolled 1240 patients ...
... the Recurrence Score(R) was 53.6 percent in males versus 53.4 percent in females, intermediate risk of recurrence was 35.2 percent in males versus 36.3 percent in females, and high risk of recurrence was 11.2 percent in males versus 10.3 percent in females. Despite the ...
... the median time to RECIST progression was 4.8, versus 2.8 for placebo.(11) BIBF 1120 is an oral ... Ingelheim Pharmaceuticals. "BIBW 2992 and BSC versus Placebo and BSC in Non-Small Cell Lung Cancer ... of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing ...
... and tolerability of pramipexole extended release versus the currently available pramipexole immediate ... release and immediate release formulations versus placebo after 18 weeks and 33 weeks of treatment, ... group, the mean change was -2.7 points at week 33 versus -4.2 points at week 18, a worsening of +1.5 ...
... of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery ... demonstrates that the cost effectiveness of PCI versus CABG depends largely on patient characteristics, ... the increase in repeat revascularization for PCI versus CABG was greatest -- CABG provided slightly more ...
... Significantly Suppressed Bone Turnover Markers versus Raloxifene in Postmenopausal Women with ... and nasopharyngitis in the arzoxifene group versus the raloxifene group, whereas significantly fewer ... About the " NEXT " Study Arzoxifene versus Raloxifene: 12-month Effects on Bone Mineral ...
... rates of serious and/or severe adverse events versus peginterferon alfa-2a - - Filing of global ... dose of albinterferon alfa-2b every two weeks, versus the treatment group receiving the standard dose ... Phase 3 Clinical Trials of Albinterferon Alfa-2b versus Peginterferon Alfa-2a HGS has conducted two ...
... treatment with the 25 mg dose and the 50 mg dose versus placebo (p < 0.01 for all comparisons). ... of 5.7 SBMs during the first week of treatment versus 1.6 SBMs per week during the baseline period. The increase in SBMs versus placebo was maintained over the 28-day treatment ...
... compared first-line XELOX (Xeloda + oxaliplatin) versus FOLFOX-4 (intravenous bolus and infusional ... using a two by factorial design, XELOX + placebo versus XELOX + Avastin (7.5 mg/kg q3w) versus FOLFOX-4 + ...
... compared with docetaxel monotherapy (9.8 versus 7.0 months, respectively). The safety ... cardiac events was 5% in the combination group versus 4% in the monotherapy group (>/= Grade 2 ... - Neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with febrile ...
... with Femara as the optimal treatment strategy versus tamoxifen EAST HANOVER, N.J., Dec. 11 ... a survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting immediately ... early significant reduction in distant metastases versus tamoxifen, at a median duration of follow-up of ...
... less clinically relevant bleeding (5.2 percent versus 7.3 percent) and less major bleeding (0.8 percent versus 3.8 percent) in those treated with ... of recurrent venous thromboembolism (2.3 percent versus 3.2 percent) and fatal or non-fatal pulmonary ...
... rates in the FCR arm (24 percent versus 13 percent, respectively). While median overall ... were similar in each treatment arm (50 percent versus 48 percent, respectively). Overall, the FCR ... darbepoetin alfa plus red blood cell transfusions versus red blood cell transfusions alone for the ...
... allopurinol for three days, with one day overlap) versus allopurinol alone, which showed a reduction in ... uric acid levels for the sequential combination versus allopurinol alone (p=0.06). Tumor lysis ... plasma uric acid >7.5mg/dL was 90% with Elitek versus 53% with allopurinol and 77% with ...
... ed Study Comparing Rituximab and Dexamethasone versus Dexamethasone Alone in ITP: Results of ... arm (2 percent in dexamethasone arm versus 6 percent in dexamethasone-plus-rituximab arm). ... compared with the traditional arm (28.7 percent versus 9.5 percent); however, no life-threatening or ...
... Statistically significant reduction in pain versus Bup/epi in patients receiving EXPAREL 450mg at ... in both EXPAREL 300mg and 450mg patient groups versus active control, 6.4 vs. 7.8 pain intensity and ... in the EXPAREL 450mg group avoided all opioid use versus zero percent (0%) of patients in the active ...
... Phase III, Randomized, Open-Label Study of 400 Mg versus 800 Mg of Imatinib Mesylate in Patients with ... International Randomized Study of Interferon versus STI571 (IRIS) 7-Year Follow-up: Sustained ... the upper limit of normal at 2 consecutive visits versus five (1.7%) patients treated with deferoxamine. ...
... test-of-cure visit was 82.2 percent for iclaprim versus 85.3 percent for linezolid in the intent-to-treat ... were: gastrointestinal disorders (7.4 percent versus 10.4 percent for iclaprim and linezolid, ... and administration site conditions (4.2 percent versus 3.9 percent); nervous system disorders ...
... group and the PCI group (13.6 percent for CABG versus 15.8 percent for PCI, p=0.44), as well as similar ... MI) for the two groups (9.1 percent for CABG versus 7.0 percent for PCI, p=0.29). As expected, ... higher in the PCI group (12.0 percent for PCI versus 6.7 percent for CABG, p=0.02), while the rate ...
... the clinical efficacy and safety of Genous versus a sirolimus-eluting stent and a bare metal stent ... of Endothelial Progenitor Cell Capture Stent versus Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent versus Bare Metal Stents in Patients Undergoing Primary ...
... Disability Status Scale (EDSS), with early versus delayed treatment. This effect first appeared at ... to patients with delayed treatment, (0.21 versus 0.27) despite the latter receiving at least three ... 2008. (2) Kappos L et al. Effect of early versus delayed interferon beta-1b treatment on ...
... achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) control (data ... showed a significant reduction in thrombus versus a standard polyurethane control, and were not statistically different in antithrombotic efficacy versus a commercially available heparin ...
... (bolus insulin) produced greater A1C reductions versus pre-mixed insulin in people with type 2 diabetes. ... compared to pre-mixed insulin (68 (47%) versus 43 (28%); p=0.0004). LANTUS(R)/APIDRA(R) provided ... costs with insulin glargine plus glulisine versus pre-mix - a prospective, observational study with ...
... also significantly reduced SLE disease activity versus placebo based on a number of other measures, ... primary efficacy endpoint of superiority versus placebo at Week 52. A clinically and ... in both belimumab treatment groups, versus placebo, had their average prednisone dose ...
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
... of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in ... controlled study with insulin glargine versus NPH human insulin ," said lead investigator ... the retinal safety profile of Lantus(R) versus NPH in 1024 patients (Lantus(R) once daily: 515 ...New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
... prebiotics had an 80% survival rate to 24 months versus a 50% survival rate for the control group rats ... reductions in cholesterol and body weight versus the control group. Significantly, the ... has repeatedly shown synergistic health benefits versus the more common single-prebiotic fibers such as ...... with methotrexate plus placebo (0.29, 0.34 versus 1.1, respectively; p<0.001). In addition, ... plus placebo-treated patients (81%, 85% versus 67%, p less than or equal to 0.0001), as measured ... a post-hoc analysis of the AMBITION ( A ctemra versus M ethotrexate double- B lind I ...
... to placebo (5 percent for tadalafil 40 mg, versus 16 percent with placebo)(4,5). Additionally, the ... mg were headache (42 percent for tadalafil 40 mg, versus 15 percent with placebo), myalgia (14 percent for tadalafil 40 mg, versus 4 percent with placebo) and flushing (13 percent ...
... at 6, 12, 18 and 24 months for lorcaserin versus placebo were 2.1% vs. 1.9% (p=0.88), 2.7% vs. ... evaluated 10 mg of lorcaserin dosed twice daily versus placebo over a two-year treatment period in obese ... 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese ...
... five years) previously demonstrated by Avandia versus metformin and sulfonylurea in the ADOPT study. ... randomized to Avandia (61 events or 2.7 percent versus 29 events or 1.3 percent) (hazard ratio=2.10, 95 ... deaths from any cause (136 events or 6.1 percent versus 157 events or 7 percent for control) (hazard ...
... a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy ... using the Barnes Akathisia Scale) for lurasidone versus placebo. Lurasidone was well-tolerated ...
... combination of vandetanib 100mg with docetaxel versus docetaxel alone. The study enrolled 1391 patients ... study evaluating vandetanib 100mg plus pemetrexed versus pemetrexed alone. The study enrolled 534 patients ... study evaluating the efficacy of vandetanib 300mg versus erlotinib 150mg. The study enrolled 1240 patients ...
... the Recurrence Score(R) was 53.6 percent in males versus 53.4 percent in females, intermediate risk of recurrence was 35.2 percent in males versus 36.3 percent in females, and high risk of recurrence was 11.2 percent in males versus 10.3 percent in females. Despite the ...
... the median time to RECIST progression was 4.8, versus 2.8 for placebo.(11) BIBF 1120 is an oral ... Ingelheim Pharmaceuticals. "BIBW 2992 and BSC versus Placebo and BSC in Non-Small Cell Lung Cancer ... of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing ...
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
... in the CYP2C19 gene that reduced its function versus 9.8 percent (N=1048) in patients without a ... attack, or stroke by 19 percent (9.9 percent versus 12.1 percent), with an increased risk of major ... (3) Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary ...Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
... in lung function from baseline of 6.6% (p=0.001 versus placebo). Lung function improved at week 6 and ... treated with Bronchitol and dornase alfa (p=0.008 versus placebo) and those being treated with Bronchitol alone (p=0.015 versus placebo). Consistent loss of lung ...... and tolerability of pramipexole extended release versus the currently available pramipexole immediate ... release and immediate release formulations versus placebo after 18 weeks and 33 weeks of treatment, ... group, the mean change was -2.7 points at week 33 versus -4.2 points at week 18, a worsening of +1.5 ...
... of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery ... demonstrates that the cost effectiveness of PCI versus CABG depends largely on patient characteristics, ... the increase in repeat revascularization for PCI versus CABG was greatest -- CABG provided slightly more ...
... Significantly Suppressed Bone Turnover Markers versus Raloxifene in Postmenopausal Women with ... and nasopharyngitis in the arzoxifene group versus the raloxifene group, whereas significantly fewer ... About the " NEXT " Study Arzoxifene versus Raloxifene: 12-month Effects on Bone Mineral ...
... rates of serious and/or severe adverse events versus peginterferon alfa-2a - - Filing of global ... dose of albinterferon alfa-2b every two weeks, versus the treatment group receiving the standard dose ... Phase 3 Clinical Trials of Albinterferon Alfa-2b versus Peginterferon Alfa-2a HGS has conducted two ...
... treatment with the 25 mg dose and the 50 mg dose versus placebo (p < 0.01 for all comparisons). ... of 5.7 SBMs during the first week of treatment versus 1.6 SBMs per week during the baseline period. The increase in SBMs versus placebo was maintained over the 28-day treatment ...
... compared first-line XELOX (Xeloda + oxaliplatin) versus FOLFOX-4 (intravenous bolus and infusional ... using a two by factorial design, XELOX + placebo versus XELOX + Avastin (7.5 mg/kg q3w) versus FOLFOX-4 + ...
... compared with docetaxel monotherapy (9.8 versus 7.0 months, respectively). The safety ... cardiac events was 5% in the combination group versus 4% in the monotherapy group (>/= Grade 2 ... - Neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with febrile ...
... with Femara as the optimal treatment strategy versus tamoxifen EAST HANOVER, N.J., Dec. 11 ... a survival benefit for an aromatase inhibitor versus tamoxifen in the monotherapy setting immediately ... early significant reduction in distant metastases versus tamoxifen, at a median duration of follow-up of ...
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
... extended-release tablets comparing tolerability versus levetiracetam immediate release (IR) and ... XR is associated with any tolerability advantages versus the same daily dose of levetiracetam IR. ... once-daily had lower rates of some adverse events versus levetiracetam IR twice-daily. -- In ...... less clinically relevant bleeding (5.2 percent versus 7.3 percent) and less major bleeding (0.8 percent versus 3.8 percent) in those treated with ... of recurrent venous thromboembolism (2.3 percent versus 3.2 percent) and fatal or non-fatal pulmonary ...
... rates in the FCR arm (24 percent versus 13 percent, respectively). While median overall ... were similar in each treatment arm (50 percent versus 48 percent, respectively). Overall, the FCR ... darbepoetin alfa plus red blood cell transfusions versus red blood cell transfusions alone for the ...
... allopurinol for three days, with one day overlap) versus allopurinol alone, which showed a reduction in ... uric acid levels for the sequential combination versus allopurinol alone (p=0.06). Tumor lysis ... plasma uric acid >7.5mg/dL was 90% with Elitek versus 53% with allopurinol and 77% with ...
... ed Study Comparing Rituximab and Dexamethasone versus Dexamethasone Alone in ITP: Results of ... arm (2 percent in dexamethasone arm versus 6 percent in dexamethasone-plus-rituximab arm). ... compared with the traditional arm (28.7 percent versus 9.5 percent); however, no life-threatening or ...
... Statistically significant reduction in pain versus Bup/epi in patients receiving EXPAREL 450mg at ... in both EXPAREL 300mg and 450mg patient groups versus active control, 6.4 vs. 7.8 pain intensity and ... in the EXPAREL 450mg group avoided all opioid use versus zero percent (0%) of patients in the active ...
... Phase III, Randomized, Open-Label Study of 400 Mg versus 800 Mg of Imatinib Mesylate in Patients with ... International Randomized Study of Interferon versus STI571 (IRIS) 7-Year Follow-up: Sustained ... the upper limit of normal at 2 consecutive visits versus five (1.7%) patients treated with deferoxamine. ...
Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD
... awakening-free nights, and rescue medication use versus placebo.(1) -- Both doses of SYMBICORT were ... mcg only), and rescue medication use versus formoterol.(3) -- Both doses of SYMBICORT were well-tolerated versus formoterol and placebo for up to 12 months.(4) ...... test-of-cure visit was 82.2 percent for iclaprim versus 85.3 percent for linezolid in the intent-to-treat ... were: gastrointestinal disorders (7.4 percent versus 10.4 percent for iclaprim and linezolid, ... and administration site conditions (4.2 percent versus 3.9 percent); nervous system disorders ...
... group and the PCI group (13.6 percent for CABG versus 15.8 percent for PCI, p=0.44), as well as similar ... MI) for the two groups (9.1 percent for CABG versus 7.0 percent for PCI, p=0.29). As expected, ... higher in the PCI group (12.0 percent for PCI versus 6.7 percent for CABG, p=0.02), while the rate ...
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
... patients in the QID group had a clinical response versus 25.0% of the placebo QID group (P < 0.0001); ... the Durezol BID patients had a clinical response versus 42.5% of patients in the placebo BID group (P ... statistically significant for the Durezol groups versus the placebo groups in both the QID and ...... the clinical efficacy and safety of Genous versus a sirolimus-eluting stent and a bare metal stent ... of Endothelial Progenitor Cell Capture Stent versus Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent versus Bare Metal Stents in Patients Undergoing Primary ...
... Disability Status Scale (EDSS), with early versus delayed treatment. This effect first appeared at ... to patients with delayed treatment, (0.21 versus 0.27) despite the latter receiving at least three ... 2008. (2) Kappos L et al. Effect of early versus delayed interferon beta-1b treatment on ...
... achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) control (data ... showed a significant reduction in thrombus versus a standard polyurethane control, and were not statistically different in antithrombotic efficacy versus a commercially available heparin ...
... (bolus insulin) produced greater A1C reductions versus pre-mixed insulin in people with type 2 diabetes. ... compared to pre-mixed insulin (68 (47%) versus 43 (28%); p=0.0004). LANTUS(R)/APIDRA(R) provided ... costs with insulin glargine plus glulisine versus pre-mix - a prospective, observational study with ...
Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma
... percentage of patients receiving SYMBICORT versus those receiving budesonide pMDI and placebo ... begin to work (except for SYMBICORT versus budesonide pMDI in Study 1 [P=.073]).(1) The ... of SYMBICORT(R) (160/4.5 micrograms) versus its Mono-Products (budesonide and formoterol) in ...Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets
... a 34.2 percent change from baseline (p=0.067, versus placebo) was seen; by Week 16, a 62.4 percent improvement from baseline was observed (p=0.038, versus placebo), showing a durable response four weeks ... an 11.2 percent change from baseline (p=0.032, versus placebo), and remained significant at Week 16 ...Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
... of aortic valve disease events alone (308 versus 326; HR 0.97; 95% CI 0.83 to 1.14). The ... (15.7%) in the simvastatin plus ezetimibe group versus 187 (20.1%) in the placebo group. The study ... than among those assigned placebo (93 [9.9%] versus 65 [7.0%]; unadjusted p=0.03), and there were ...Other ContentsOther Tags
(Date:6/18/2013)... 2013 The herbal extract of a yellow-flowered mountain ... increase the lifespan of fruit fly populations by an ... , But it,s how Rhodiola rosea ... grabbed the attention of study leaders Mahtab Jafari and ... in a manner completely unrelated to dietary restriction and ...
(Date:6/18/2013)... shows that weight gain and increased head size in the first ... at early school age. , The study was led by University ... 13,800 children who were born full-term. , The results, published in ... put on 40% of their birthweight in the first four weeks ... six years of age, compared with babies who only put on ...
(Date:6/17/2013)... June 17, 2013 An international team led ... Howard Hughes Medical Institute and Albert Einstein College of ... new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium ... effort to help solve one of the major global ... its dangerous drug-resistant strains," said Peter G. Schultz, the ...
Breaking Biology News(10 mins):Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2IQ link to baby's weight gain in first month 2New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4(Date:6/19/2013)... Bonita ™ Hair Skin and Nail ... many conditions that range from hair breakage and split ... has now developed a single serving, rapid response tablet ... only stronger than the original Bonita formula, but also ... , Justin Zehrung, Vice President of Essential Source ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The ... for Disease Control of the 2500 to 3000 citizens, ... cancer called mesothelioma this year, about one third will ... Navy Veteran diagnosed with this asbestos exposure form of ... them instant access to the nations most skilled mesothelioma ...
(Date:6/19/2013)... 19, 2013 Faith4Kidz is starting a new ... Peace". Faith4Kidz would like help showing support for kids to ... are more positive. Check out the website, http://www.gracenfaith.com ... logo is red, white and blue stars as a symbol ... throughout history as well as the stars we should encourage ...
(Date:6/18/2013)... June 18, 2013 Exposed Skin Care has ... of acne suffers of all ages finally achieve the clear, ... treatment products, this new acne clearing system combines the power ... prevent new acne from forming. , After a ... these products are some of the most effective available on ...
(Date:6/18/2013)... Looking for a way to break out of the ... IWALKAWAKE is a guide to unlocking one’s true potential through ... on harnessing the powerful and abundant spiritual presence that is ... guide to finding one’s true purpose and potential. These nine ... to reach their true potential. The awakenings deal with subjects ...
Breaking Medicine News(10 mins):Health News:Essential Source ® Improves On Best Selling Bonita ™ Hair Skin and Nail Product 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3Health News:Faith4Kidz Introduces Patriotic Hats to Benefit the "Grace in Faith Equals Peace" Mission 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3[0] Essential Source ® Improves On Best Selling Bonita ™ Hair Skin and Nail Product[0] Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation[0] Faith4Kidz Introduces Patriotic Hats to Benefit the "Grace in Faith Equals Peace" Mission[0] Exposed Skin Care Review Released by ExposedSkinCareReview.org[0] Learn How To Stop Sleepwalking Through Life in New Book 'IWALKAWAKE'
EPREXhealtcorrectingTearconvalescestammeringblowsnacrolepsymicromedicalECGtretedtelesurgeryflushesascertained
Other Tags| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |